Active substance
Fenoldopam
- US FDA 5
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| CORLOPAM | EQ 10MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | injectable · injection | HOSPIRA | Discontinued | 23 Sep 1997 |
| FENOLDOPAM MESYLATE | EQ 10MG BASE/ML | injectable · injection | LUITPOLD | Discontinued | 1 Dec 2003 |
| FENOLDOPAM MESYLATE | EQ 10MG BASE/ML | injectable · injection | HIKMA | Discontinued | 12 Oct 2004 |
| FENOLDOPAM MESYLATE | EQ 10MG BASE/ML | injectable · injection | SANDOZ | Discontinued | 15 Feb 2005 |
| FENOLDOPAM MESYLATE | EQ 10MG BASE/ML | injectable · injection | TEVA PARENTERAL | Discontinued | 7 Mar 2007 |
Safety signals and safety-related labeling changes
- US FDA 2 Sep 2020 CORLOPAM — safety-related labeling change
Labeling sections changed: Adverse Reactions; Use in Specific Populations
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.